Clinical Trial

A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

Study acronym: Rimegepant PMS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-23.
Trial Details
NCT Number NCT07497854
Lead Sponsor Pfizer
Conditions Migraine With or Without Aura
Enrollment 3,000 participants
Start Date 2026-10-01
Primary Completion 2030-07-31 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15